Evidence mapPaperPMID 27367724Full record

Trial reportNutrients2016

Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis.

Silvia M Ferolla, Cláudia A Couto, Luciana Costa-Silva, Geyza N A Armiliato, Cristiano A S Pereira, Flaviano S Martins, Maria de Lourdes A Ferrari, Eduardo G Vilela, Henrique O G Torres, Aloísio S Cunha and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06491342 (PROBIOTIC SUPPLEMENT VERSUS PLACEBO FOR DECREASE STEATOSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE), which is not on this map. Cited by 64 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 13 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06491342 nacompletednot on this mapstarted 2024, after this paper: background citation

Probiotic supplement versus placebo for decrease steatosis in metabolic dysfunction-associated steatotic liver disease (masld): a multicenter, randomized, double-blind, placebo-controlled trial

TypeinterventionalSponsorPhramongkutklao College of Medicine and HospitalRan2024 to 2025Enrolled90ConditionsFatty Liver, NonalcoholicArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 13 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.Computational and mathematical methods in medicine · 2022
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Silvia M FerollaDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. contato@silviaferolla.com.br.
Cláudia A CoutoDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. clacouto@hotmail.com.
Luciana Costa-SilvaDepartamento de Anatomia e Imagem, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. lucianacosta@me.com.
Geyza N A ArmiliatoDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. geyzaarmiliato@hotmail.com.
Cristiano A S PereiraDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. cristiano_asp@hotmail.com.
Flaviano S MartinsDepartamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte31270-901, Brazil. flaviano@icb.ufmg.br.
Maria de Lourdes A FerrariDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. lferrari@medicina.ufmg.br.
Eduardo G VilelaDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. egarciavilela985@gmail.com.
Henrique O G TorresDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. henrique.gamatorres@gmail.com.
Aloísio S CunhaDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. aloisio@medicina.ufmg.br.
Teresa C A FerrariDepartamento de ClínicaMédica, Faculdade de Medicina, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Brazil. tferrari@medicina.ufmg.br.
Hospital das Clínicas da Universidade Federal de Minas Gerais · BRUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nonalcoholic fatty liver disease is the most prevalent chronic liver disease in Western countries; it can progress to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocarcinoma. The importance of gut-liver-adipose tissue axis has become evident and treatments targeting gut microbiota may improve inflammatory and metabolic parameters in NASH patients. In a randomized, controlled clinical trial, involving 50 biopsy-proven NASH patients, we investigated the effects of synbiotic supplementation on metabolic parameters, hepatic steatosis, intestinal permeability, small intestinal bacterial overgrowth (SIBO) and lipopolysaccharide (LPS) serum levels. Patients were separated into two groups receiving Lactobacillus reuteri with guar gum and inulin for three months and healthy balanced nutritional counseling versus nutritional counseling alone. Before and after the intervention we assessed steatosis by magnetic resonance imaging, intestinal permeability by lactulose/mannitol urinary excretion and SIBO by glucose breath testing. NASH patients presented high gut permeability, but low prevalence of SIBO. After the intervention, only the synbiotic group presented a reduction in steatosis, lost weight, diminished BMI and waist circumference measurement. Synbiotic did not improve intestinal permeability or LPS levels. We concluded that synbiotic supplementation associated with nutritional counseling seems superior to nutritional counseling alone for NASH treatment as it attenuates steatosis and may help to achieve weight loss.

Indexed as

Gastrointestinal MicrobiomeAdultAgedBody Mass IndexFemaleHumansIntestinal MucosaIntestinesLipopolysaccharidesLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseasePermeabilitySynbioticsWaist CircumferenceLipopolysaccharidesgut microbiotahepatic steatosisintestinal permeabilitylipopolysaccharidenonalcoholic fatty liver diseasenonalcoholic steatohepatitisobesityprobioticsynbioticweight loss

Identifiers

PMID27367724
PMCPMC4963873
OpenAlexW2471964074

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.